Johnson & Johnson (NYSE:JNJ) on Thursday shared topline data from the Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha ...

Nipocalimab combo therapy showed no added efficacy over anti-TNFα treatment in the Phase 2a trial. Johnson & Johnson ended the RA study but sees over $5 billion in potential for nipocalimab. Get a ...

“What I love most about our new box program is it’s priced and sized right to be approachable for any customer. Being able to order online or in store and pick up at any Southern Steer location offers ...